Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387602353> ?p ?o ?g. }
- W4387602353 abstract "Aim Wolfram Syndrome (WS) is a rare condition caused by mutations in Wfs1 , with a poor prognosis and no cure. Mono-agonists targeting the incretin glucagon-like-peptide 1 (GLP-1) have demonstrated disease-modifying potential in pre-clinical and clinical settings. Dual agonists that target GLP-1 and glucose-dependent insulinotropic polypeptide (GIP-1) are reportedly more efficacious; hence, we evaluated the therapeutic potential of dual incretin agonism in a loss-of-function rat model of WS. Methods Eight-month-old Wfs1 knock-out (KO) and wild-type control rats were continuously treated with either the dual agonist DA-CH5 or saline for four months. Glycemic profile, visual acuity and hearing sensitivity were longitudinally monitored pre-treatment, and then at 10.5 and 12 months. Pancreata and retina were harvested for immunohistological analysis. Results DA-CH5 therapy reversed glucose intolerance in KO rats and provided lasting anti-diabetogenic protection. Treatment also reversed intra-islet alterations, including reduced endocrine islet area and β-cell density, indicating its regenerative potential. Although no rescue effect was noted for hearing loss, visual acuity and retinal ganglion cell density were better preserved in DA-CH5-treated rats. Conclusion We present preclinical evidence for the pleiotropic therapeutic effects of long-term dual incretin agonist treatment; effects were seen despite treatment beginning after symptom-onset, indicating reversal of disease progression. Dual incretins represent a promising therapeutic avenue for WS patients." @default.
- W4387602353 created "2023-10-14" @default.
- W4387602353 creator A5028452806 @default.
- W4387602353 creator A5028708572 @default.
- W4387602353 creator A5029241731 @default.
- W4387602353 creator A5048622515 @default.
- W4387602353 creator A5055783760 @default.
- W4387602353 creator A5072489475 @default.
- W4387602353 creator A5075013832 @default.
- W4387602353 creator A5079150060 @default.
- W4387602353 creator A5084581276 @default.
- W4387602353 date "2023-10-13" @default.
- W4387602353 modified "2023-10-14" @default.
- W4387602353 title "Treatment with the dual-incretin agonist DA-CH5 demonstrates potent therapeutic effect in a rat model of Wolfram Syndrome" @default.
- W4387602353 cites W1631372304 @default.
- W4387602353 cites W1971474519 @default.
- W4387602353 cites W1977843578 @default.
- W4387602353 cites W1979535675 @default.
- W4387602353 cites W1985305554 @default.
- W4387602353 cites W1992748149 @default.
- W4387602353 cites W1999400548 @default.
- W4387602353 cites W2016147073 @default.
- W4387602353 cites W2038467165 @default.
- W4387602353 cites W2039127036 @default.
- W4387602353 cites W2044832929 @default.
- W4387602353 cites W2049434572 @default.
- W4387602353 cites W2049808069 @default.
- W4387602353 cites W2050397606 @default.
- W4387602353 cites W2076843631 @default.
- W4387602353 cites W2082156652 @default.
- W4387602353 cites W2094346774 @default.
- W4387602353 cites W2112234186 @default.
- W4387602353 cites W2125364438 @default.
- W4387602353 cites W2125928547 @default.
- W4387602353 cites W2126743348 @default.
- W4387602353 cites W2134285290 @default.
- W4387602353 cites W2149717292 @default.
- W4387602353 cites W2161085583 @default.
- W4387602353 cites W2161155577 @default.
- W4387602353 cites W2166113890 @default.
- W4387602353 cites W2169158685 @default.
- W4387602353 cites W2234697191 @default.
- W4387602353 cites W2324493635 @default.
- W4387602353 cites W2341140560 @default.
- W4387602353 cites W2559389868 @default.
- W4387602353 cites W2599792256 @default.
- W4387602353 cites W2741958922 @default.
- W4387602353 cites W2749562418 @default.
- W4387602353 cites W2770385888 @default.
- W4387602353 cites W2784560430 @default.
- W4387602353 cites W2785903681 @default.
- W4387602353 cites W2788211509 @default.
- W4387602353 cites W2791252329 @default.
- W4387602353 cites W2800843957 @default.
- W4387602353 cites W2809773616 @default.
- W4387602353 cites W2811221346 @default.
- W4387602353 cites W2884113305 @default.
- W4387602353 cites W2895666357 @default.
- W4387602353 cites W2941039646 @default.
- W4387602353 cites W2955438150 @default.
- W4387602353 cites W2963909599 @default.
- W4387602353 cites W2982670142 @default.
- W4387602353 cites W3000000012 @default.
- W4387602353 cites W3004172664 @default.
- W4387602353 cites W3025085904 @default.
- W4387602353 cites W3045729180 @default.
- W4387602353 cites W3045828365 @default.
- W4387602353 cites W3046420687 @default.
- W4387602353 cites W3082016244 @default.
- W4387602353 cites W3093409345 @default.
- W4387602353 cites W3118579634 @default.
- W4387602353 cites W3122403678 @default.
- W4387602353 cites W3125424605 @default.
- W4387602353 cites W3127014820 @default.
- W4387602353 cites W3134075201 @default.
- W4387602353 cites W3167017992 @default.
- W4387602353 cites W3200195576 @default.
- W4387602353 cites W3202950944 @default.
- W4387602353 cites W3211105320 @default.
- W4387602353 cites W4200318305 @default.
- W4387602353 cites W4210826800 @default.
- W4387602353 cites W4214752489 @default.
- W4387602353 cites W4221123392 @default.
- W4387602353 cites W4224861850 @default.
- W4387602353 cites W4245486276 @default.
- W4387602353 cites W4283165920 @default.
- W4387602353 cites W4296711520 @default.
- W4387602353 cites W4310595709 @default.
- W4387602353 cites W4312065477 @default.
- W4387602353 cites W4316494583 @default.
- W4387602353 cites W4361273223 @default.
- W4387602353 cites W4361274882 @default.
- W4387602353 doi "https://doi.org/10.3389/fendo.2023.1234925" @default.
- W4387602353 hasPublicationYear "2023" @default.
- W4387602353 type Work @default.
- W4387602353 citedByCount "0" @default.
- W4387602353 crossrefType "journal-article" @default.
- W4387602353 hasAuthorship W4387602353A5028452806 @default.
- W4387602353 hasAuthorship W4387602353A5028708572 @default.
- W4387602353 hasAuthorship W4387602353A5029241731 @default.